Refillable Drug Reservoirs for Retinal Vascular Diseases.

IF 4.1 1区 医学 Q1 OPHTHALMOLOGY
Andrew J Clark, Carl Regillo, Shamika Gune, Dante J Pieramici
{"title":"Refillable Drug Reservoirs for Retinal Vascular Diseases.","authors":"Andrew J Clark, Carl Regillo, Shamika Gune, Dante J Pieramici","doi":"10.1016/j.ajo.2024.11.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Most patients with retinal vascular disease require chronic, regular treatments to maximize visual potential. This places a challenging burden on the patient and is one reason why real-world visual outcomes often lag the results seen in clinical trials.</p><p><strong>Review: </strong>Sustained drug delivery devices have long been considered one way to alleviate this difficulty. In particular, devices with refillable reservoirs aim to take advantage of existing drugs to improve their pharmacokinetics and reduce treatment frequency. Very few devices utilizing a refillable reservoir have reached human clinical trials, however. Only one, the Port Delivery System (PDS) with ranibizumab, has received FDA approval. Despite this milestone, the PDS was voluntarily withdrawn one year after its introduction due to product quality challenges related to the septum of the device. The PDS was recently returned to the market following modifications to the implant as well as the refill-exchange needle.</p><p><strong>Conclusion: </strong>Although devices with refillable reservoirs have increased challenges related to their inherent complexity, the potential for improved patient outcomes merit further development of this technology.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajo.2024.11.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Most patients with retinal vascular disease require chronic, regular treatments to maximize visual potential. This places a challenging burden on the patient and is one reason why real-world visual outcomes often lag the results seen in clinical trials.

Review: Sustained drug delivery devices have long been considered one way to alleviate this difficulty. In particular, devices with refillable reservoirs aim to take advantage of existing drugs to improve their pharmacokinetics and reduce treatment frequency. Very few devices utilizing a refillable reservoir have reached human clinical trials, however. Only one, the Port Delivery System (PDS) with ranibizumab, has received FDA approval. Despite this milestone, the PDS was voluntarily withdrawn one year after its introduction due to product quality challenges related to the septum of the device. The PDS was recently returned to the market following modifications to the implant as well as the refill-exchange needle.

Conclusion: Although devices with refillable reservoirs have increased challenges related to their inherent complexity, the potential for improved patient outcomes merit further development of this technology.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.20
自引率
7.10%
发文量
406
审稿时长
36 days
期刊介绍: The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect. The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports. Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信